Ketoprofen (Ketofen)

Ketoprofen, marketed under the brand name Ketofen for veterinary use, is a non-steroidal anti-inflammatory drug (NSAID) approved for use in horses to manage pain and inflammation associated with musculoskeletal disorders. This medication belongs to the propionic acid class of NSAIDs and has been used in equine medicine for decades, providing veterinarians with an effective tool for managing acute inflammatory conditions. Ketoprofen offers a valuable alternative within the NSAID class, with characteristics that make it particularly suited for certain clinical applications in equine patients.

The mechanism of action for ketoprofen involves inhibition of cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins and other inflammatory mediators responsible for pain, inflammation, and fever. Ketoprofen demonstrates inhibition of both COX-1 and COX-2 isoforms, providing broad anti-inflammatory effects. Additionally, ketoprofen may inhibit lipoxygenase pathways to some degree, potentially contributing to its anti-inflammatory activity through mechanisms beyond prostaglandin inhibition alone. The result is effective reduction of the cardinal signs of inflammation including swelling, heat, pain, and loss of function in affected tissues.

Ketoprofen for equine use is available as a sterile injectable solution formulated for intravenous administration. The concentration is typically 100 mg/mL, allowing convenient dosing across the wide range of horse body weights. Administration is performed intravenously, with onset of action occurring relatively rapidly after injection. The duration of effect is generally considered intermediate among equine NSAIDs, typically providing 12 to 24 hours of therapeutic benefit depending on the condition being treated and individual patient factors. The injectable-only formulation means that ketoprofen is typically used for acute conditions rather than long-term management.

The safety profile of ketoprofen in horses reflects the class-wide concerns associated with all NSAIDs, including potential for gastrointestinal ulceration and renal effects. When used according to labeled directions for appropriate indications, ketoprofen is generally well-tolerated by most horses. However, the same precautions that apply to all NSAIDs must be observed, most critically the absolute prohibition against combining ketoprofen with other NSAIDs. NSAID stacking dramatically increases toxicity risk and can result in life-threatening complications. Veterinary supervision ensures appropriate patient selection, proper dosing, and monitoring for adverse effects during treatment.

The primary labeled indication for ketoprofen in horses is the alleviation of inflammation and pain associated with musculoskeletal disorders. This broad category encompasses numerous conditions that horses commonly experience, including acute soft tissue injuries, joint inflammation, tendon and ligament strains, and muscle soreness. Athletic and performance horses frequently develop musculoskeletal inflammation due to the physical demands of training and competition, making effective anti-inflammatory therapy an important component of their healthcare. Ketoprofen provides relief that helps maintain comfort during recovery and rehabilitation from these common conditions.

Beyond its primary musculoskeletal indication, ketoprofen demonstrates effectiveness for various other painful and inflammatory conditions in horses. Post-operative pain management represents an important application, where the medication helps control inflammation and discomfort following surgical procedures. The anti-inflammatory effects reduce swelling at surgical sites and contribute to patient comfort during the recovery period. When combined with appropriate supportive care, ketoprofen helps horses recover more comfortably from both minor and major surgical interventions.

Colic pain management occasionally involves ketoprofen, though flunixin meglumine (Banamine) typically remains the preferred NSAID for visceral pain in horses. However, ketoprofen can be effective for mild to moderate colic presentations and may be selected when flunixin is not available or when the veterinarian prefers an alternative within the NSAID class. The mechanism of action is similar, with prostaglandin inhibition providing analgesia for abdominal pain. As with any colic presentation, appropriate diagnostic evaluation should accompany pain management to ensure serious conditions are not masked.

Additional clinical applications for ketoprofen include management of other inflammatory conditions where NSAID therapy is indicated. Eye inflammation, respiratory tract inflammation, and other soft tissue inflammatory conditions may respond to ketoprofen's anti-inflammatory effects. The medication's injectable formulation makes it particularly useful for horses that cannot receive oral medications or when rapid onset of action is desired. Some veterinarians prefer ketoprofen for certain applications based on their clinical experience with the medication's effects in specific situations.

When selecting ketoprofen over other available NSAIDs, veterinarians consider several factors. The injectable-only formulation makes ketoprofen suitable for acute situations but less practical for ongoing maintenance therapy, where oral NSAIDs like phenylbutazone or firocoxib are typically preferred. Some practitioners perceive differences in efficacy or side effect profiles between different NSAIDs for specific conditions, though direct comparative studies in horses are limited. Cost, availability, and familiarity also influence selection. The most important consideration is that only one NSAID should be used at a time, with appropriate washout periods observed when switching between medications in this class.

Dosing protocols for ketoprofen in horses follow established guidelines, with the specific regimen determined by the veterinarian based on the condition being treated and individual patient factors. The labeled dose for horses is 2.2 mg/kg (1 mg/lb) administered intravenously once daily. This dose has been established through pharmacokinetic and clinical studies to provide effective anti-inflammatory and analgesic effects while maintaining an acceptable safety profile. Accurate weight determination is essential for proper dosing, as both underdosing and overdosing can compromise treatment outcomes. Weight tapes provide reasonable estimates, though scales offer greater accuracy when available.

The frequency of ketoprofen administration is typically once daily, reflecting the medication's pharmacokinetic profile in horses. The duration of anti-inflammatory effect generally allows for adequate coverage with single daily doses for most conditions. Some veterinarians may adjust dosing frequency based on the severity of the condition and individual patient response, but this should only occur under direct veterinary supervision. Maximum daily doses should not be exceeded, as higher doses increase the risk of adverse effects without necessarily providing additional therapeutic benefit.

Treatment duration with ketoprofen should be limited to the shortest period necessary to manage the condition being treated. The labeled maximum treatment duration is five consecutive days, reflecting concerns about cumulative gastrointestinal and renal toxicity associated with prolonged NSAID use. Many acute conditions require only one to three days of treatment. Extended therapy beyond labeled duration requires careful veterinary oversight with appropriate monitoring. Horses requiring longer-term anti-inflammatory management may be transitioned to oral NSAID formulations or managed with alternative strategies.

Administration of ketoprofen requires proper intravenous injection technique. The medication should be administered by slow IV injection, typically over 30 seconds or more, to minimize the potential for adverse reactions. The injection should be given through a clean, properly placed IV catheter or by direct venipuncture using appropriate aseptic technique. Ketoprofen is not labeled for intramuscular or subcutaneous administration in horses, and these routes should not be used. Following injection, horses should be observed briefly for any immediate adverse reactions, though these are uncommon with proper administration.

If a dose of ketoprofen is missed during a prescribed treatment course, the appropriate response depends on the timing and clinical situation. A dose given late can be administered when remembered, then the regular schedule resumed with the next dose. Doses should never be doubled to compensate for missed doses, as this increases toxicity risk. If the horse's pain or inflammation returns before the next scheduled dose, veterinary consultation is appropriate to determine whether timing adjustments are needed or whether additional evaluation is warranted.

Completion of the prescribed treatment course is important for optimal outcomes, though treatment should not extend beyond what is clinically necessary. Horses should be monitored for return of pain or inflammation after treatment ends, as persistent signs may indicate incompletely resolved underlying conditions. Competition horses must observe appropriate withdrawal times after treatment completion, as ketoprofen is a prohibited substance under most equestrian sport regulations. The veterinarian provides guidance on expected withdrawal periods based on the dose and duration of treatment.

Ketoprofen shares the class-wide side effect profile common to all non-steroidal anti-inflammatory drugs, with gastrointestinal effects representing the most significant concern. When administered according to labeled directions in appropriate patients, most horses tolerate ketoprofen without experiencing clinically significant adverse effects. However, understanding the potential for side effects enables early recognition and intervention should problems develop. Horse owners should be aware of what to monitor during treatment and when to contact their veterinarian with concerns.

The gastrointestinal tract represents the primary site of potential NSAID toxicity, including ketoprofen. Inhibition of prostaglandin synthesis reduces the protective mucus layer that normally shields the stomach and intestinal lining from digestive acids and other irritants. This predisposes horses to gastric ulceration and may contribute to right dorsal colitis with prolonged use. Signs of gastrointestinal disturbance may include decreased appetite, mild colic signs, changes in manure consistency, teeth grinding (bruxism), and excessive salivation. These effects are more likely with higher doses, longer treatment durations, and in horses with pre-existing gastrointestinal compromise.

Renal effects represent another category of potential ketoprofen side effects. Prostaglandins help maintain renal blood flow, particularly in horses experiencing dehydration, cardiovascular compromise, or other stressors. NSAID-induced prostaglandin inhibition can reduce kidney perfusion in vulnerable patients, potentially leading to acute kidney injury. Risk factors include dehydration, concurrent nephrotoxic medications, pre-existing renal disease, and cardiovascular instability. Signs of renal problems may include decreased urine output, changes in drinking behavior, and laboratory abnormalities on blood work.

Serious side effects requiring immediate veterinary attention include signs of severe gastrointestinal ulceration such as teeth grinding, excessive salivation, persistent colic despite treatment, dark or bloody manure, and profound depression. Protein-losing enteropathy manifesting as peripheral edema (ventral edema, limb swelling) indicates serious intestinal damage requiring urgent intervention. Signs of anaphylaxis including facial swelling, hives, respiratory distress, or cardiovascular collapse require immediate emergency care. While these severe reactions are uncommon, their potential severity warrants awareness.

As with all NSAIDs, the risk of right dorsal colitis deserves special attention. This condition involves ulceration and inflammation of a specific section of the large intestine, potentially leading to life-threatening protein loss, diarrhea, colic, and death. While any NSAID can contribute to this condition, the risk increases dramatically when multiple NSAIDs are used simultaneously or in rapid succession. Prevention through appropriate NSAID use, avoiding NSAID stacking, and limiting treatment duration represents the best approach. Early recognition and aggressive treatment improve outcomes should this complication develop.

The most critical contraindication for ketoprofen is concurrent use with other non-steroidal anti-inflammatory drugs. NSAID stacking is absolutely contraindicated because it dramatically increases the risk of life-threatening gastrointestinal ulceration, right dorsal colitis, and renal papillary necrosis. This prohibition applies regardless of the specific NSAIDs involved or how different they may seem. Ketoprofen must never be combined with phenylbutazone (Bute), flunixin meglumine (Banamine), firocoxib (Equioxx), meloxicam (Metacam), aspirin, or any other NSAID. When switching between NSAIDs is clinically necessary, appropriate washout periods of at least 24-48 hours should be observed, with some practitioners recommending longer intervals.

Known hypersensitivity or previous adverse reaction to ketoprofen or other NSAIDs represents a contraindication to use. Horses that have experienced allergic reactions, severe gastrointestinal complications, or renal problems with any NSAID may be at increased risk for similar reactions to ketoprofen. Cross-reactivity between different NSAIDs can occur, meaning adverse reactions to one medication in this class should prompt caution with all others. Complete medication history disclosure to the veterinarian enables identification of at-risk patients before treatment begins.

Pre-existing gastrointestinal disease significantly affects the safety of ketoprofen administration. Horses with known gastric ulcers, history of right dorsal colitis, inflammatory bowel disease, or other gastrointestinal compromise are at higher risk for NSAID-induced complications. Similarly, horses recovering from gastrointestinal surgery or recent colic episodes may have compromised mucosal barriers that increase vulnerability to NSAID toxicity. Alternative analgesic approaches may be more appropriate in these patients, or gastroprotective strategies should be implemented if NSAID therapy is deemed necessary.

Renal compromise represents another important contraindication or precaution for ketoprofen use. Horses with pre-existing kidney disease, those experiencing dehydration or hypovolemia, and those receiving other nephrotoxic medications are at increased risk for NSAID-induced renal injury. Adequate hydration should be ensured before and during NSAID therapy. Geriatric horses commonly have some degree of reduced renal function and warrant careful consideration before NSAID administration. Pregnant mares, breeding animals, and competition horses require special consideration regarding the appropriateness of ketoprofen therapy given their specific circumstances.

The interaction between ketoprofen and other NSAIDs constitutes the most dangerous and critical drug interaction to understand. Concurrent use of multiple NSAIDs is absolutely contraindicated due to dramatically increased risk of severe gastrointestinal ulceration, right dorsal colitis, renal papillary necrosis, and potentially fatal outcomes. This interaction applies to all NSAIDs including phenylbutazone, flunixin meglumine, firocoxib, meloxicam, and aspirin. Ketoprofen should never be combined with any of these medications. When switching between NSAIDs becomes clinically necessary, appropriate washout periods of at least 24-48 hours must be observed to allow clearance of the first medication before introducing the second.

The combination of ketoprofen with corticosteroids also increases gastrointestinal toxicity risk and requires careful consideration. Both drug classes impair gastrointestinal mucosal protective mechanisms through different pathways, and their concurrent use significantly raises the probability of ulceration. If both anti-inflammatory drug types are clinically needed, they should ideally be administered at different times with appropriate spacing between them, and gastroprotective therapy should be strongly considered. Horses on long-term corticosteroid therapy for chronic conditions require careful planning if NSAID therapy becomes necessary.

Ketoprofen can interact with medications affecting kidney function or renal blood flow. Concurrent administration with aminoglycoside antibiotics (such as gentamicin or amikacin), which have nephrotoxic potential, increases the risk of kidney damage. Other potentially nephrotoxic medications should similarly be used cautiously in horses receiving ketoprofen. Diuretics like furosemide may have reduced effectiveness when given with NSAIDs, and the combination may also increase renal risks. Careful monitoring and hydration support help manage these interactions when concurrent use is necessary.

Competition horses receiving ketoprofen must be aware that drug interactions can affect both detection times and regulatory compliance. The presence of multiple medications may complicate clearance and potentially extend the period during which prohibited substances can be detected. Ketoprofen is a prohibited substance under FEI, USEF, and state racing commission regulations. Detection times and withdrawal recommendations should be obtained from current regulatory body guidelines, as these can change. Maintaining detailed medication records and consulting with veterinarians familiar with competition regulations helps ensure compliance.

Monitoring requirements for horses receiving ketoprofen focus on early detection of adverse effects, particularly gastrointestinal and renal complications. Owners should observe their horses for signs of decreased appetite, changes in manure consistency or frequency, signs of abdominal discomfort, excessive salivation, teeth grinding, or general demeanor changes. These signs may indicate developing gastrointestinal problems requiring veterinary attention. For horses receiving extended treatment or those with risk factors, periodic blood work to assess kidney function and protein levels may be recommended. Fecal occult blood testing can help detect gastrointestinal bleeding.

Special populations within equine patients require additional precautions when ketoprofen is administered. Geriatric horses commonly have reduced organ function and may be more susceptible to NSAID-induced complications, potentially requiring dose adjustments or enhanced monitoring. Foals have immature metabolic systems and may handle medications differently than adult horses. Horses with concurrent systemic illnesses, particularly those affecting fluid balance or cardiovascular function, may have altered drug handling and increased susceptibility to adverse effects. Pregnant mares and breeding animals require careful consideration of the appropriateness of NSAID therapy.

Competition and performance horses face particular concerns regarding ketoprofen use due to its prohibited status under most equestrian sport regulations. The FEI includes ketoprofen on its prohibited substances list, as do USEF, state racing commissions, and most breed-specific show organizations. Detection times vary based on dose, duration of treatment, and testing sensitivity. Conservative withdrawal times should be observed, and competition horse owners should consult current regulations from the relevant governing body before making competition decisions. Accurate documentation of treatment dates, doses, and administration routes is essential for regulatory compliance.

Proper administration technique is important for ketoprofen safety. The medication is labeled for intravenous use only in horses and should be administered by slow IV injection. Care should be taken to ensure proper placement of the injection, avoiding inadvertent perivascular or intra-arterial administration. The horse should be adequately restrained to prevent movement during injection. Following administration, brief observation for any immediate adverse reactions is appropriate, though such reactions are uncommon with proper technique.

Long-term use considerations for ketoprofen emphasize limiting treatment duration to minimize cumulative toxicity risk. The labeled maximum of five consecutive days reflects safety concerns with prolonged NSAID exposure. Horses requiring ongoing anti-inflammatory therapy may be better served by oral NSAID formulations suitable for longer-term use, potentially with gastroprotective strategies. Regular veterinary reassessment helps ensure continued treatment remains appropriate and that alternative approaches are considered when possible.

Proper storage of ketoprofen ensures medication stability and effectiveness throughout the labeled shelf life. The injectable formulation should be stored according to manufacturer specifications, typically at controlled room temperature between 20-25°C (68-77°F), with protection from light and freezing. The medication should remain in its original container with proper closure until use. Multi-dose vials should be handled according to facility protocols for multi-use containers, with attention to sterile access, dating, and discard timelines. Storage locations should be secure and organized to prevent confusion between different medications.

Handling precautions for ketoprofen focus on proper administration technique and personal protection. When preparing injections, aseptic technique should be employed to maintain sterility of the medication. Gloves should be worn during handling and administration. Care should be taken to avoid needle sticks or splashing of medication onto skin or mucous membranes. While ketoprofen has relatively low human toxicity risk from incidental contact, minimizing unnecessary exposure to any veterinary medication represents appropriate practice. Equipment used for administration should be disposed of properly.

Expiration dates should be strictly observed, and any medication showing signs of degradation should not be used. Visual inspection of the injectable solution should confirm clarity without particulate matter, discoloration, or cloudiness. Medications that have been frozen should not be used. Expired or degraded medications should be disposed of according to local regulations for pharmaceutical waste. Inventory management should ensure that medications approaching expiration are identified and replaced while adequate supplies remain available for patient care needs.

Draft horses and other large breeds present considerations for ketoprofen administration related to their significant body mass. These horses, weighing 1,600 to 2,200 pounds or more, require accurate weight determination for appropriate dosing. While no specific breed-related differences in ketoprofen metabolism have been documented in draft breeds, their size necessitates larger total drug amounts to achieve therapeutic plasma concentrations. Weight tapes may be less accurate in draft breeds due to their unique body conformation, so scales are preferred when available. Standard weight-based dosing of 2.2 mg/kg applies regardless of breed.

Light horse breeds including Thoroughbreds, Quarter Horses, Arabians, and Warmbloods represent the populations in which ketoprofen and other equine NSAIDs have been most extensively used. Standard dosing recommendations apply to these breeds without modification. Breed-specific conditions may affect overall treatment planning but do not specifically alter ketoprofen pharmacology. Quarter Horses with genetic conditions like HYPP or PSSM may require pain management for associated episodes but do not have specific contraindications to ketoprofen. Thoroughbreds commonly receive NSAIDs for racing-related musculoskeletal conditions, with appropriate attention to withdrawal time requirements.

Ponies and miniature horses require careful dose calculation given their smaller body mass. The weight-based dosing principle remains the same, but accurate weight measurement becomes especially important as small errors represent larger proportional differences in these smaller animals. Ponies commonly affected by equine metabolic syndrome or prone to laminitis may require NSAID therapy for pain management, with attention to the overall treatment plan. Standard formulation concentrations may make precise dosing more challenging in very small equines, requiring careful measurement.

Breed-specific genetic conditions do not create specific contraindications to ketoprofen but may affect the overall clinical context in which the medication is used. Friesians with their predisposition to certain conditions require comprehensive health assessment as with any patient. Appaloosas requiring pain management for conditions including equine recurrent uveitis may receive NSAIDs as part of their treatment protocol. Warmbloods and sport horses commonly receive NSAIDs for competition-related injuries and must observe appropriate withdrawal times. Individual patient assessment should guide medication decisions regardless of breed background.

Within the NSAID drug class, several alternatives to ketoprofen are available for equine pain management and anti-inflammatory therapy. Phenylbutazone (Bute) is the most commonly used oral NSAID for musculoskeletal conditions in horses and offers cost advantages for longer-term management. Flunixin meglumine (Banamine) provides superior visceral analgesia and is typically preferred for colic pain. Firocoxib (Equioxx) is a COX-2 preferential NSAID with potentially improved gastrointestinal safety, available in both injectable and oral forms. Meloxicam (Metacam) provides another option with once-daily dosing. Each NSAID has specific characteristics that may make it more suitable for particular applications. The critical principle is that these medications must never be combined, and appropriate washout periods must be observed when switching between them.

Alternative analgesic approaches working through different mechanisms may be used instead of or in combination with NSAIDs. Alpha-2 agonists including xylazine and detomidine provide sedation and analgesia through different pathways and are valuable for acute pain management. Opioid analgesics such as butorphanol offer visceral pain relief without the gastrointestinal concerns of NSAIDs. Lidocaine continuous rate infusion provides analgesic and prokinetic effects in hospitalized patients. Local and regional anesthesia techniques provide targeted pain relief. Multimodal analgesia combining medications from different classes can provide superior pain control while potentially allowing lower doses of individual medications.

Complementary and supportive therapies often accompany NSAID treatment as part of comprehensive patient care. Gastroprotective medications including omeprazole help protect against NSAID-induced gastric ulceration and may be recommended for horses receiving extended NSAID therapy or those with ulcer risk factors. Physical therapy modalities including cold therapy, controlled exercise, and therapeutic interventions complement pharmaceutical pain management. Rest and appropriate management modifications support recovery from musculoskeletal conditions. Non-pharmaceutical approaches should be considered as part of any comprehensive treatment plan. Any medication substitution or modification should occur only under direct veterinary guidance.